Neurologists from the Independent Public Clinical Hospital No. 4 in Lublin are testing a breakthrough therapy used to treat myasthenia gravis. Doctors used a well-known substance and have already achieved their first successes. Their research was described, among others, by in the prestigious journal Nature reviews neurology, more and more is said about this discovery in the world. Neurologists need about PLN 30 million to continue their research.
A breakthrough therapy for the treatment of myasthenia gravis
Neurologists from the hospital in Lublin were the first in the world to use cladribine in the treatment of severe myasthenia gravis. This substance has been known for several decades and is used, inter alia, in in the treatment of multiple sclerosis. After administering cladribine to the patient in whom the medicine was tested, the doctors observed that the symptoms of the disease began to improve. The dyspnea is gone, the patient has felt better, maybe even getting up.
Several centers in Poland are interested in starting clinical trials on the effectiveness of this therapy. However, their start depends on money. Doctors applied for a grant in the amount of PLN 20-30 million to the Medical Research Agency. Now they are waiting for consideration.
See also:
- Breakthrough therapies. The key to the development of medicine
- Without modern therapies, there will be no development of medicine
- Innovative therapies. Hope for Life
Rapid initiation of clinical trials will allow faster registration of the therapeutic method. If doctors do not do it, the innovative method can be registered by one of the pharmaceutical companies. The same was the case with another discovery of scientists from Lublin concerning the specific use of cladribine in the treatment of multiple sclerosis. It is important that the entity registering the method in the future may count on profits from the commercialization of the project.
What is myasthenia gravis?
Myasthenia gravis is an autoimmune disease. The immune system recognizes the body’s own tissues as foreign and produces antibodies to fight them. In myasthenia gravis, antibodies are produced against the antigens of the neuromuscular junction, which in turn leads to muscle dysfunction.
The first symptoms of myasthenia gravis can be difficult to spot with drooping eyelids and double vision. After that, the disease affects the muscles of the throat and larynx, and over time, patients also have problems maintaining an upright posture and moving.
In about half of patients, myasthenia gravis resolves spontaneously, in almost 40% of them there is a significant improvement. From 2 to 5 percent patients die as a result of myasthenic crisis – failure caused by the involvement of the respiratory muscles.
Clinical trials with cladribine should be cheaper as it is not a completely new drug on the market.
Editors recommend:
- Innovative drugs not for Poles?
- There is hope for people with MS. Polish scientists have discovered an effective therapy
- A breakthrough discovery of Poles in the fight against leukemia
You haven’t been able to find the cause of your ailments for a long time? Do you want to tell us your story or draw attention to a common health problem? Write to the address [email protected] #Together we can do more
The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website.
Source: RMF24.pl